<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997282</url>
  </required_header>
  <id_info>
    <org_study_id>262-09-001</org_study_id>
    <secondary_id>JapicCTI-090904</secondary_id>
    <nct_id>NCT00997282</nct_id>
  </id_info>
  <brief_title>A Study of OPC-262 in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-arms Parallel Group Comparative Study of OPC-262 in Patients With Type 2 Diabetes (Phase 2/3 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the superiority of the efficacy of OPC-262
      (2.5 mg, and 5 mg) to placebo in patients with type 2 diabetes after 24 week treatment in a
      double-blind fashion and to evaluate the safety of OPC-262 to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in HbA1C from baseline</measure>
    <time_frame>Week 24 (LOCF)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood glucose (FBG) from baseline</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 2 hour postprandial blood glucose (PPG) from baseline</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 3 hour PPG AUC from baseline</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>OPC-262 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally administered once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-262 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally administered once daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>orally administered once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-262 2.5 mg</intervention_name>
    <description>orally administered once daily for 24 weeks</description>
    <arm_group_label>OPC-262 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-262 5 mg</intervention_name>
    <description>orally administered once daily for 24 weeks</description>
    <arm_group_label>OPC-262 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally administered once daily for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes patients with HbA1C above 6.5% and below 10%

          2. Patients who are capable of giving informed consent

          3. Patients who are able to take contraceptive measures to avoid pregnancy of the patient
             or the patient's partner for the entire study period and for 4 weeks after the study
             (end of the post-observation period)

        Exclusion Criteria:

          1. Patients with type 1 diabetes mellitus, patients with diabetes mellitus due to other
             specified drugs, mechanisms or diseases, and patients with gestational diabetes
             mellitus

          2. Patients with a medical history of diabetic coma

          3. Patients with poorly-controlled hypertension

          4. Patients with heart failure

          5. Patients with a complication of active hepatitis or hepatic cirrhosis

          6. Patients undergoing treatment of glomerular diseases other than diabetic nephropathy

          7. Patients with a history or complication of malignant tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaatsuhisa Saito</last_name>
    <role>Study Chair</role>
    <affiliation>OPCJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>January 6, 2014</last_update_submitted>
  <last_update_submitted_qc>January 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2014</last_update_posted>
  <responsible_party>
    <name_title>Katsuhisa Saito, Senior Operating Officer</name_title>
    <organization>Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

